During the past two decades, monoclonal antibodies (mAb) have emerged as an important new drug class. Currently, over a dozen mAbs have been approved for therapeutic use in the United States for various clinical indications, including oncology, chronic inflammatory diseases, transplantation, infectious diseases and cardiovascular diseases. One of the advantages of mAb therapeutics is that they belong to a well‐established drug class that has a high success rate from the first use in humans through receipt of regulatory approval: 29% for chimeric mAbs and 25% for humanized mAbs, while the success rate for small molecule drugs is only 11% .
Compugen has developed a proprietary mAb‐target discovery computational platform to identify novel drug targets. The identification of novel mAb targets is addressed using Compugen’s unique approach of integrating various public and proprietary data sources and generating specific computational discovery engines, tailor‐made for the desired disease state and protein family.